Novo Nordisk/X
Aug 2, 2025, 03:50
FDA Approves Novo Nordisk Prophylactic Treatment for Hemophilia A and B
Novo Nordisk US has shared a proud post on X:
“PRESS: Novo Nordisk receives US FDA approval for a new indication for a prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B without inhibitors. ”
To learn more, follow the link.
Stay informed with Hemostasis Today.
-
May 28, 2026, 13:42Claudio Laudani: Balancing Ischemic and Bleeding Risk in AF with Coronary Disease
-
May 28, 2026, 13:30When it Comes to Stroke Care, Quality Matters – Duke Health
-
May 28, 2026, 13:29Natalie Johnson: Transforming PE Care Through Endovascular Innovation
-
May 28, 2026, 13:16Francisco Chacón-Lozsán: Anticoagulation Strategies for Complex ICU Patients
-
May 28, 2026, 12:57Ahmed Kardousha: Protecting Growth and Fertility in Transfusion-Dependent β-Thalassemia
-
May 28, 2026, 12:36Kabilan K L: Key Nursing Considerations for Abciximab Therapy
-
May 28, 2026, 12:17Astha Thakkar: Practical Approaches to Platelet Thresholds in ITP
-
May 28, 2026, 09:16Maxime Dely: The Human Connection Behind Stem Cell Donation
-
May 28, 2026, 09:15Heghine Khachatryan: Maternal Health Begins With Recognizing Iron Deficiency Early